FILE- This April 26, 2017, file photo shows the Eli Lilly and Co. corporate headquarters in Indianapolis. Eli Lilly is offering a half-price version of its top-selling insulin Humalog as drugmakers face growing pressure to control prices. The drugmaker says it will introduce a version of the diabetes treatment called Insulin Lispro with a list price 50 percent lower than its current rate, about $275 per vial.
“We are fortunate to have entered into an agreement with Lilly given its global development capability, oncology expertise, and the radiopharmaceutical experience and capabilities Lilly is building following the acquisition of POINT Biopharma,” said Paul Grayson, CEO of Radionetics Oncology. The funding builds on a previous round in October, bringing the total Series B financing to $100 million. The funding round last fall included Nvidia, Ascenta Capital, Abingworth and others.“Iambic is a true innovator, both in the demonstrated accuracy and speed of its state-of-the art AI drug discovery models, and its ability to rapidly advance candidates from discovery and into human studies,” said Ayman AlAbdallah, partner at Mubadala Capital.
The overall goal of its approach to developing treatments is homing in on the genetic drivers of diseases.